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ABSTRACT (246 words)  
 
Aims: 
To determine the incidence and severity of self-reported hypoglycaemia in a primary 
care population with type 2 diabetes. The study also aimed to compare incidence by 
treatment regimen. 
Materials and methods:  
A prospective observational study in 17 centres throughout the UK. Recruitment was 
based on treatment regimen (metformin, sulfonylurea, insulin or incretin-based 
therapy). Participants were asked to keep a blood glucose diary and self-report 
hypoglycaemia episodes (non-severe (self-treated) and severe (requiring external 
help), over a 12-month period.  
Results: 
 SDUWLFLSDQWV ZHUH HQUROOHG RI ZKRP   UHWXUQHG  PRQWKO\ GLDU\
Overall, 39% reported experiencing hypoglycaemiaUHFRUGHGV\PSWRPDWLF
HSLVRGHQRQ-severe and VHYHUH%\WUHDWPHQWLQFLGHQFHHYHQWVSHU
person/year) for any hypoglycaemia type was 4.39 for insulin, 2.34 sulfonylurea, 0.76 
metformin and 0.56 incretin-based. Compared to metformin, risk of non-severe 
hypoglycaemia was around three times higher for participants on sulfonylureas and 
over five times higher for those on insulin (IRR 3.02 [1.76- 5.18], p<0.001, and IRR 
5.96 [3.48-10.2], p<0.001, respectively). For severe episodes, the incidence for 
sulfonylurea (0.09) was similar to metformin (0.07) and incretin-based (0.07); for 
insulin the risk remained almost five times higher than metformin (incidence 0.32; 
IRR 4.55 [1.28-16.20], p=0.019).  
Conclusions: 
Hypoglycaemia represents a substantial burden for people with type 2 diabetes. 
Sulfonylureas and insulin are both associated with a risk of reported non-severe 
hypoglycaemia, but only insulin with severe episodes. This suggests the importance 
of the continued use of sulfonylureas in appropriate patients with type 2 diabetes.    
 
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Trial registration: 
NCT02666521, CLINICALTRIALS.GOV 
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INTRODUCTION 
Good glycaemic control is a major goal of diabetes management and is associated 
with fewer diabetes-related complications [1-4]. Hypoglycaemia remains a common 
and potentially hazardous complication of treatment, and is the principal limiting 
factor preventing individuals from achieving optimal glycaemic control through 
intensive treatment [5]. 
 
Although Type 2 diabetes (T2DM) comprises most cases of diabetes [6], the overall 
incidence of hypoglycaemia and associated risk factors in people with T2DM have 
not been documented as exhaustively as in Type 1 diabetes (T1DM). Previous 
studies in T2DM have often had methodological limitations. A large meta-analysis 
containing over 530,000 individuals with T2DM estimated an annual incidence of 0.8 
severe and 19 non-severe episodes per-person-year (PPY) [7]. However, these 
estimates may be inaccurate as hypoglycaemia was often variably defined, and 
many retrospective or cross-sectional studies are subject to poor recall and under-
estimate the frequency. More recently, a prospective study involving 23,627 people 
with T1DM and T2DM from 24 countries similarly reported hypoglycaemia incidence 
at 19.3 events PPY for T2DM [8]. Although examining a large cohort, the period of 
follow up was short (4 weeks). The UK Hypoglycaemia Group Study prospectively 
studied hypoglycaemia incidence over 12 months. However, this study, which was 
conducted more than a decade ago, recruited individuals with good glycaemic 
control from specialist centres, and may not be representative of the wider 
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population with T2DM [9]. Since it was conducted, newer anti-hyperglycaemic drugs 
with a lower risk of hypoglycaemia have been introduced [10, 11]. Additionally, more 
patients are managed in generalist settings, as models for diabetes care have 
become primary care-centred [12], and glycaemic thresholds for reporting 
hypoglycaemia have been updated [13, 14]. A prospective study was therefore 
warranted that included newer therapies for diabetes and conducted in people who 
were managed exclusively within primary care.  
 
Of mutual importance is the consideration of factors associated with hypoglycaemia 
development which influence an individuals risk. A study which identified 
hypoglycaemia rates within routine clinical practice would identify individuals who 
may be at greater risk and help in determining personalised glycaemic targets. 
 
The present study aimed to prospectively examine rates of hypoglycaemia in a 
general population with T2DM managed in primary care. Specific objectives 
included: 1) to determine the incidence and severity of self-reported hypoglycaemia, 
over a 12-month period; 2) to compare hypoglycaemia episodes by treatment 
regimen; and 3) to explore associated predictors. 
ǤǤ
  
 
MATERIALS AND METHODS 
This prospective observational study was conducted in UK primary care settings 
between July 2012 and August 2016. Participants were recruited via volunteer 
general practices.   
 
EOLJLELOLW\LQFOXGHG7'0GLDJQRVHGPRQWKVUHFHLYLQJRQHRIWKHIROORZLQJ
treatment regimens, i) metformin alone, ii) sulfonylurea-based iii) insulin-based, or iv) 
incretin-based therapy (dipeptidyl peptidase-4 (DPP-4) inhibitor or glucagon-like 
peptide-1 receptor agonists (GLP-1RA). (Further inclusion/exclusion criteria and full 
methods, see Supplementary Appendix S1) 
 
Practice staff collected key study data at baseline (and 12-months). Participants 
prospectively self-recorded data on: 1) capillary blood glucose  UHDGLQJV/week) 
using a blood glucose meter and test strips (Accu-Chek, Roche Diabetes Care Ltd, 
UK) and entered details in a monthly diary; and 2) hypoglycaemia episodes (date, 
time, symptom intensity, blood glucose, remedial treatment/action taken) 
immediately after the event using a study-specific form.  
 
Primary outcomes included the frequency of non-severe (self-treated) 
hypoglycaemia episodes: 1) SURSRUWLRQRISDUWLFLSDQWVZKRH[SHULHQFHGepisode 
during the follow-up period (on which the sample size was calculated); and 2) 
incidence of self-reported hypoglycaemia episodes. Secondary outcomes included 
ǤǤ
  
 
the frequency of: severe (requiring external help), symptomatic and nocturnal 
hypoglycaemia.  
 
Sample size 
The UK Prospective Diabetes Study reported that 6.3% of participants experienced 
non-severe hypoglycaemia event during follow up [15]. The UK Hypoglycaemia 
Study Group showed that 39% of participants taking sulfonylureas and 64% for 
insulin, experienced  hypoglycaemia event within 12-months of follow up [9]. 
Based on the findings of the LEAD trial, it was anticipated that around 10% of people 
taking a GLP-1RA  would report hypoglycaemia within the last year [16]. Incidence in 
those taking DDP-4 inhibitors was likely to be significantly lower than those taking 
GLP-1RAs [17]. Therefore, a conservative estimate of 10% was used for the incretin 
group. Our original sample size (total n= 422) was based on an assessment of these 
differences. Recruitment of 140 participants to both the sulfonylurea and the insulin 
groups, 62 taking metformin alone and 80 on incretin-based therapies, would give 
80% power to detect these differences, accounting for a potential 50% loss through 
drop out or switching treatment. 
 
Statistical methods 
The overall SURSRUWLRQ RI SDUWLFLSDQWV KDYLQJ  HSLVRGH RI hypoglycaemia 
(any/symptomatic/severe/non-severe/nocturnal) and the proportion by treatment 
group were calculated, based on participants who returned 1 diary. Incidence of 
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hypoglycaemia (PPY) was also calculated; follow-up time was calculated using 
diaries, based on the number of weeks participants were contributing data to the 
study. Negative binomial regression was used to calculate the incidence rate with 
robust SEs and specifying a log-transformed exposure time offset term.  Logistic 
regression was used to assess the association between hypoglycaemia and key 
variables: age, sex, ethnicity, diabetes duration, hypoglycaemia awareness score, 
body mass index, estimated glomerular filtration rate (eGFR), HbA1c and 
cardiovascular disease.   
 
Sensitivity analyses were conducted, excluding participants who changed treatment 
group during the study period. Hypoglycaemia experience in participants who were 
PRUHRUOHVVHQJDJHGZLWKWKHVWXG\FRQWULEXWHGRUWKHPean number of weeks 
of diary data) and by frequency of blood glucose monitoring (UHFRUGHG  or < the 
mean number of measurements/week), were also explored. Stata version 14 
(StataCorp) was used to conduct all analyses. Statistical significance related to 
p<0.05 and 95% confidence intervals (CI) are presented.  
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RESULTS 
Recruitment and follow-up 
From 23 general practices that initially volunteered and received training in study 
procedures, 17 practices recruited participants (Scotland n=1, Wales n=2, England 
n=14). Subsequently, 325 eligible participants were enrolled into the study 
(Supplementary Figure S1), (median per practice, n=19, range 554).  At baseline, 
recruitment according to treatment regimen was metformin alone n=75, sulfonylurea-
based n=107, insulin-based n=93, and incretin-based n=50 (GLP-1RA, n=14; DPP-4 
inhibitors, n=36).  
 
A total of 306 participants (94%) completed 12 months in the study. Self-recording of 
blood glucose and hypoglycaemia events was variable but 84% (n=274) of 
SDUWLFLSDQWVUHWXUQHGPRQWKO\GLDU\RYHUPRQWKVRIGLDU\GDWDDQGRYHU
30% returned all 12 months (Supplementary Figure S1); mean number of weeks 
37.0 (SD±16.95). Follow-up data were collected for most participants (self-
completion questionnaire n= 239; key medical record data n=303).  
 
Further details on anti-hyperglycaemic drugs prescribed (single/dual therapy 
combinations) within each treatment group are outlined in Supplementary Table S1. 
  
Demographic and biomedical characteristics 
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Table 1 provides participant characteristics (mean age 62.6 (SD±12.0) years; 91% of 
white ethnicity; 61% male). Overall, 62% of participants had no previous experience 
of severe hypoglycaemia and 45% for insulin. For non-severe, this varied from 17% 
(insulin) to 60% (incretin-based), who had never experienced hypoglycaemia. 
 
Frequency of hypoglycaemia 
In the 12-months of follow-up, overall 39.2% (95%CI 33.445.0) of participants 
experienced  hypoglycaemia episode. Of these, 92% experienced 1 non-severe 
episode, 17% 1 severe and 53% 1 nocturnal episode. According to baseline 
treatment, the proportion for insulin was 56.4% (45.267.0), sulfonylurea 51.6% 
(41.461.8), metformin 18.8% (10.930.3) and incretin-based 9.8% (3.623.6), 
(Table 2). All episodes were reported as symptomatic for metformin and incretin-
based therapies. The majority were symptomatic for sulfonylurea (~70%) and insulin 
(~80%). For non-severe episodes, overall, 35.8% experienced , approximately half 
of people on insulin (51.3%) and sulfonylurea (48.4%) had 1, with substantially 
lower rates for metformin (17.2%) and incretin-based (7.3%). For severe, overall, 
6.6% experienced 1 episode, with 11.5% for insulin and around 4% for other 
agents. Nocturnal episodes were experienced by 41.0% for insulin but fewer for 
other groups (sulfonylurea 19.8%, metformin 7.8%, incretin-based 4.9%).   
 
Incidence of any hypoglycaemia (PPY) ranged from 4.39 for insulin, 2.34 
sulfonylurea, 0.76 metformin and 0.56 incretin-based, (Table 3). In comparison to 
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metformin, the incidence rate ratio was significantly higher for both sulfonylurea (IRR 
3.09 [95%CI 1.835.21], p<0.001) and insulin (5.79 [3.449.74], p<0.001). The trend 
was similar for symptomatic episodes; the risk with blood glucose level  WR
PPRO/ was around six times higher for participants on sulfonylurea and 
approximately nine times higher for insulin, IRR 6.29 (2.7914.16; p<0.001) and 9.16 
(4.0820.50; p<0.001), respectively. For serious hypoglycaemia (blood glucose 
<3.0mmol/L), comparison was not possible as no episodes were experienced by 
participants on metformin. The risk of nocturnal episodes was substantially higher for 
both sulfonylurea and insulin in comparison to metformin, IRR 2.67 (1.136.28; 
p=0.025) and 7.48 (3.2917.0; p<0.001), respectively. For non-severe episodes the 
trend remained similar, sulfonylurea IRR 3.02 (1.765.18; p<0.001) and insulin 5.96 
(3.4810.2; p<0.001). For severe episodes the incidence was similar for metformin, 
incretin-based and sulfonylurea (PPY, 0.07, 0.07 and 0.09, respectively); in 
comparison, the rate for insulin was significantly higher (IR 0.32 [95%CI 0.190.53]; 
IRR 4.55 [95%CI 1.2816.2], p=0.019), (Table 3).  
 
Sensitivity analyses, excluding participants who changed treatment group from 
baseline (~20%), suggested that hypoglycaemia frequency remained broadly similar 
(Supplementary Table S2 and S3). Compared to metformin (IR 0.69), the incidence 
(95%CI) of symptomatic hypoglycaemia (all) became significantly lower for incretin-
based (IR 0.24 [0.090.61]; IRR 0.34 [0.120.99], p=0.049), although the number 
involved was very small (n= 3). Comparison of SDUWLFLSDQWVZKRFRQWULEXWHGRU
ǤǤ
  
 
the mean (37 weeks) of diary data, found risk of nocturnal hypoglycaemia was 
slightly higher for participants who were less engaged (IRR 0.35 [0.220.58], 
p<0.001), but there were no significant differences for risk of severe, non-severe and 
symptomatic episodes (data not shown); both groups had a similar history of 
previous hypoglycaemia (severe and non-severe), at recruitment.  Taking into 
account the frequency of blood glucose self-monitoring  RU  WKH PHan (5.3) 
number of measurements/week recorded in diaries), risk of non-symptomatic 
hypoglycaemia was slightly higher for participants who measured more frequently 
(IRR 0.17 [0.06-0.47], p=0.001). There were no differences for symptomatic 
episodes (data not shown). 
 
Factors associated with hypoglycaemia episodes 
Diabetes duration was found to be significantly associated with a small (45%) 
increased risk of any, non-severe or symptomatic episodes, unadjusted. After 
adjusting for treatment group, age and ethnicity, only symptomatic episodes 
remained associated (OR 1.05 [95%CI 1.011.10]), (Figure 1, Supplementary Table 
S4, S5 and S6). Older adults aged \HDUVZHUHaround 50% less likely to have 
any, non-severe or symptomatic episodes, compared to those <65 years; OR 0.45 
(0.240.84), 0.50 (0.270.94) and 0.44 (0.240.83), respectively, adjusted for 
treatment group, ethnicity and diabetes duration. Hypoglycaemia awareness score 
was associated with a small (15%) lower risk of non-severe and symptomatic 
episodes, but no associations were seen following multi-variate adjustment.  
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Participants of non-white ethnicity were around 70% less likely to have any (OR 0.26 
[0.080.82]) hypoglycaemia episodes compared to those of white ethnicity (adjusted 
for treatment group, age and diabetes duration), and non-severe reached borderline 
significance (OR 0.33 [0.101.04]), (Figure 1), Supplementary Table S4 and S6. No 
significant associations were found with any factors for severe hypoglycaemia, 
(Supplementary Table S7). Unfortunately, ethnicity could not be explored as a risk 
factor in these additional analyses as no severe episodes were recorded for non-
white participants, (Supplementary Table S8). 
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DISCUSSION 
In the present study, incidence rates (PPY) for non-severe hypoglycaemia ranged 
from 3.84 for insulin and 1.94 for sulfonylurea, to 0.64 and 0.49 for metformin and 
incretin-based therapy, respectively. For severe episodes, surprisingly the incidence 
for those treated with sulfonylureas (0.09) was very similar to metformin and incretin-
based, but the incidence was significantly higher with insulin (0.32), which was to be 
expected. 
 
The rates observed in our study indicate that hypoglycaemia episodes continue to 
represent a substantial burden for people with T2DM and were comparable to those 
reported in previous studies.  
 
For insulin, the prevalence we observed is broadly similar to that found for T2DM by 
previous prospective studies, including the large global HAT study [8] and the UK 
Hypoglycaemia Study [9]. In contrast, generally the overall incidence of 
hypoglycaemia observed in the present study for insulin (4.39 PPY) is substantially 
lower than previous estimates for Northern Europe/Canada (18.1) [8] and the UK 
(16.36) [18]. However, our study provided a much longer duration of prospective 
follow-up (12-months) with a mean of 37 (SD±17) weeks of diary data, compared to 
the one month diary data collected in the other studies [8, 18]. Furthermore, for 
severe events the rates we observed were similar to those found previously by 
Donnelly et al (0.35 PPY) [18].  
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For sulfonylureas, the hypoglycaemia rates observed (48% experienced  non-
severe; 4% experienced  VHYHUH; incidence 0.09 PPY) were similar to those 
reported by the UK Hypoglycaemia Study Group QRQ-severe episode; 7% 
 VHYHUH LQFLGHQFH  33<, based on prospective data captured over 9-10 
months [9]. However, the UK Hypoglycaemia Group Study was conducted >10 years 
ago, and studied people with diabetes who were managed in secondary care 
specialist centres. Although, a similar rate of severe hypoglycaemia (0.08 PPY) for 
secretagogues (including sulfonylurea) was reported by the more recent Italian 
Hypos-1 study, estimated from participant re-call over the previous 4 weeks [19].   
 
Metformin and incretin-based therapies are generally associated with a very low risk 
of hypoglycaemia [15, 20]. The rates of non-severe and severe episodes we 
observed were low but higher than anticipated, particularly for severe episodes (0.07 
PPY for both metformin and incretin-based). Unfortunately, in the present study, we 
were unable to account for participant level factors, such as reduced dietary 
intake/fasting, increased physical activity/exercise or alcohol consumption, which 
may have contributed to hypoglycaemia risk.  We also need to acknowledge the 
subjective nature of self-recording hypoglycaemia episodes and the reliance on 
individuals to record episodes in event diaries, which may have introduced bias. 
Severe episodes were based on the need for third party assistance (not blood 
glucose level). However, this required both participant reporting of the need for 
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assistance and third party confirmation. Cases of severe hypoglycaemia in people on 
metformin (monotherapy) have previously been reported in the literature [21-24]. 
Furthermore, for non-severe hypoglycaemia, a recent model-based meta-analysis of 
trial data suggests a small increased risk for both metformin (RR~2.0 ) and GLP1-
RAs (RR up to 3.1), compared to placebo [25].  
 
In our study, ROGHUDGXOWVDJHG\HDUVZHUH~50% less likely to have experienced 
most types of hypoglycaemia (with the exception of severe), compared to those aged 
<65. Previous studies have demonstrated a modestly lower risk of any (IRR 0.99) [8] 
and symptomatic (IRR 0.98) episodes [19], for each additional year of age. 
Perceived symptoms of hypoglycaemia differ in older people [26], and may lead to 
under recognition/reporting [27].  In our study, no difference in hypoglycaemia 
awareness score was observed at recruitment, but previous history of severe 
hypoglycaemia  HSLVRGH\HDU was higher in older 65 years compared to 
younger participants, (20.5% vs 10.2%, respectively, p=0.018). No difference was 
observed for non-severe episodes. 
 
The association between diabetes duration and a small but higher risk of 
hypoglycaemia that was observed in our study is consistent with the report from the 
Hypos-1 study [19], of OR 1.10 and RR 1.02, respectively, for symptomatic 
episodes. However, in contrast to the Hypos-1 study, no association was found for 
the above factors with severe episodes. Data to allow comparison with ethnic 
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differences we found are scarce. However, lower rates of severe hypoglycaemia 
have previously been observed for people of Asian and of Latino extraction 
compared to white ethnicity [28], and a higher risk for people identified as African 
American/Black compared to white ethnicity [28, 29]. 
 
The role of renal impairment on the risk of hypoglycaemia has previously been 
highlighted, particularly for patients on sulfonylurea and insulin based treatment 
regimens [30]. In our study, renal insufficiency was not shown to be a predictor of 
hypoglycaemia, including after adjustment for treatment group. However, the number 
of participants who had moderate/severe renal impairment (eGFR <60ml/min) at 
baseline was low.  
 
Considerable variation was observed in the number of times people chose to 
measure their blood glucose routinely (participants were asked to perform /week, 
and some did considerably more). However, when collating data, this could be used 
as an indicator of being actively engaged in the study. Therefore, for analysis 
purposes, if a participant was poorly engaged and did not return a hypoglycaemia 
recording form we could take account of this, rather than assume that 
hypoglycaemia was not experienced during a particular week/period. A further 
strength is the availability of blood glucose readings for most reported episodes, 
enabling both alert level (PPRO/ PJG/) and serious, clinically important 
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hypoglycaemia (<3.0mmol/L (54mg/dL)) to be identified, as proposed for more 
transparent reporting in clinical studies [13]. 
 
Unfortunately, despite a robust recruitment approach, we did not reach our planned 
study sample size. This will have limited our ability to detect significant differences 
between treatment classes. At practice level, despite originally aiming to involve 
more general practices, some practices which had shown an interest and received 
training to participate did not take part in the study. Implications regarding staff 
changes, staff availability and a lack of approval to conduct the study in certain 
localities (because of perceived prescribing implications for meters and test strips 
following study cessation) led to difficulties in practice recruitment. At participant 
level, the number enrolled fell short of target. This was primarily as a result of 
changes in prescribing guidance/practices (to include a wider choice of add-on 
therapies/intensification options) over the study duration [31], and the combination of 
treatment regimens allowed for study eligibility, which caused difficulties in 
recruitment of certain treatment groups, particularly those on incretin-based therapy. 
A further limitation is that it was not possible to include SGLT-2 inhibitors as a 
treatment class, as they were not licensed for use in the UK until after the study had 
commenced. 
 
The study aimed to include a general population with T2DM to reflect real world 
practice. However, despite broad inclusion criteria, potential for selection bias still 
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exists. By excluding people treated solely in secondary care, whose needs are more 
complex, people with more problematical hypoglycaemia could be absent from the 
study population. Conversely, people with previous hypoglycaemia problems may 
have been more willing to volunteer for the study. Anticipated health benefits and 
better care are known to motivate people to participate in research [32, 33]. 
 
Because of the limited number of hypoglycaemia events recorded (overall, n=107 
H[SHULHQFHGHSLVRGHDQGWKHQXPEHUVZHUHPXFKOHVVLQVRPHFDWHJRULHVthis 
may have limited the power to compare treatment groups. Particularly, between 
those were you would expect to see a small difference in hypoglycaemia rates, and 
for incretin-based therapies where the numbers recruited were small. Furthermore, 
we were unable to explore possible differences in hypoglycaemia rates between 
specific anti-hyperglycaemic therapies (or dosing regimens) within each treatment 
class. This is something that future studies and analyses may want to consider.  
 
In the present study, the observed lower incidence of severe hypoglycaemia for 
participants prescribed sulfonylureas compared to those on insulin is in agreement 
with findings from previous observational studies, and adds support to the continued 
importance of sulfonylureas as a possible therapy choice in T2DM, for certain 
patients, especially in low-income and middle-income countries [34]. However, the 
incidence of non-severe episodes still represents a significant burden, given the 
potential impact on an individuals daily activities and wellbeing [35, 36], the 
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economic consequences of reduced work productivity and increased treatment costs 
[37], and the associated increased risk of severe events [38]. Risk prediction of 
hypoglycaemia is an important area for both research and clinical practice.  Future 
research should consider further identification of potential risk factors, including 
ethnicity, to help individualise therapy choices to give a lower risk of hypoglycaemia. 
 
Conclusion 
The present study contributes to the contemporary evidence for rates of 
hypoglycaemia for patients with T2DM treated in primary care and the substantial 
burden of hypoglycaemia in T2DM. For appropriate patients, sulfonylureas continue 
to be an important treatment option. Further consideration of factors associated with 
hypoglycaemia could help identify at risk groups and inform ways to individualise 
therapy choices and glycaemic targets.   
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LEGEND TO FIGURES 
 
 
 
 
Figure 1: Risk factors for hypoglycaemia (any type of episode) 
 
1 Model adjusted for treatment group at baseline 
2
 Model adjusted for treatment group, age, ethnic group, diabetes duration 
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MAIN TABLES  
 
Table 1: Key characteristics of participants  
Characteristics All 
n = 325 
Metformin 
n = 75 
Sulfonylurea 
n = 107 
Insulin 
n = 93 
Incretin-based 
n = 50 
P-value* 
Demographic       
Age (years) 62.6 (± 11.95) 59.3 (13.27) 63.3 (11.07) 65.4 (11.66) 60.4(10.92) 0.005 
Aged ш65 158 (48.6) 33 (44.0) 53 (49.5) 55 (59.1) 17 (34.7) 0.035 
Sex, Male, n (%) 198 (60.9) 46 (61.3) 67 (62.6) 56 (60.2) 29 (58.0) 0.954 
Ethnicity, n (%)       
White 294 (90.5) 70 (93.3) 92 (86.0) 88 (94.6) 44 (88.0) 0.410 
Asian 22 (6.8) 4 (5.3) 10 (9.4) 3 (3.2) 5 (10.0)  
Black 5 (1.5) 0 3 (2.8) 2 (2.2) 0  
Mixed 4 (1.2) 1 (1.3) 2 (1.9) 0 1 (2.0)  
Biomedical Measurements       
BMI (kg/m
2
) 31.7 (± 6.37) 31.30 (± 6.18) 31.54 (± 6.14) 30.88 (± 6.22) 34.13 (± 6.95) 0.028 
Systolic BP (mmHg) 129.8 (± 13.36) 130.65 (± 12.29) 130.43 (± 14.29) 130.42 (± 14.04)   126.26(±11.13) 0.236 
HDL Cholesterol (mmol/l) 1.21 (± 0.42) 1.23 (± 0.38) 1.20 (± 0.49) 1.26 (± 0.42) 1.10 (± 0.25) 0.238 
LDL Cholesterol (mmol/l) 2.03 (± 0.76) 1.92 (± 0.61) 2.03 (± 0.70) 2.18 (± 0.87) 1.91 (± 0.81) 0.167 
HbA1c (mmol/mol) - baseline 
                           (%) 
56.5(±10.72); 
7.3(±0.98) 
52.0(±10.38); 
6.9(±0.95) 
55.5(±9.42);  
7.2(±0.86) 
61.0(±11.3);  
7.7(±1.03)  
56.6(±9.80);  
7.3(±0.90) 
<0.001 
< 58 mmol/mol, n (%) 183 (56.3) 56 (74.7) 66 (61.7) 33 (35.5) 28 (56.0) <0.001 
< 53 mmol/mol, n (%)  130 (40.0) 45 (60.0) 47 (43.9) 20 (21.5) 18 (36.0) <0.001 
< 48 mmol/mol, n (%) 78 (24.0) 31 (41.3) 23 (21.5) 14 (15.1) 10 (20.0) 0.327 
HbA1c (mmol/mol)  12 months 
                           (%) 
56.2(±13.56); 
7.3(±1.24) 
49.6(±10.48); 
6.7(±0.96) 
54.7(±11.89); 
7.2 (±1.09) 
62.4(±14.32); 
7.9 (±1.31) 
57.3(±14.69); 
7.4 (±1.34) 
<0.001 
< 58 mmol/mol, n (%) 189 (58.2) 60 (80.0) 68 (63.6) 32 (34.4) 29 (58.0) 0.144 
< 53 mmol/mol, n (%) 143 (44.0) 49 (65.3) 49 (45.8) 23 (24.7) 22 (44.0) 0.117 
 
< 48 mmol/mol, n (%) 103 (31.7) 39 (52.0) 34 (31.8) 15 (16.1) 15 (30.0) 0.089 
 
eGFR ш90 ml/min 95 (29.2) 16 (24.2) 35 (33.7) 25 (27.8) 19 (39.6) 0.003 
 
60-89 ml/min 171 (52.6) 46 (69.7) 59 (56.7) 41 (45.6) 25 (52.1)  
30-59 ml/min 40 (12.3) 4 (6.1) 10 (9.6) 22 (24.4) 4 (8.3)  
ч 29 ml/min 2 (0.6) 0 
 
0 
 
2 (2.22) 0  
Medical history       
Duration of diagnosed diabetes (years, 
IQR) 
8 (4-12) 4 (2-7) 8 (4-11) 13 (8-18) 6.5 (3-10) <0.001 
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Co-morbidities, n (%)       
Stroke 15 (4.6) 1 (1.3) 6 (5.6) 6 (6.5) 2 (4.0) 0.419 
 
Coronary heart disease 
(IHD, MI, angioplasty, angina) 
60 (18.5) 13 (17.3) 17 (15.9) 21 (22.6) 9 (18.0) 0.662 
 
Peripheral arterial disease 
(or leg angioplasty) 
4 (1.2) 1 (1.3) 1 (0.9) 2 (2.2) 0 0.716 
Retinopathy 34 (10.5) 4 (5.3) 6 (5.6) 21 (22.6) 3 (6.0) <0.001 
Smoking status: current, n (%)  44 (13.5) 5 (6. 7) 18 (17.0) 18 (20.0) 3 (6.1) 0.024 
Alcohol intake, n (%)       
Never  96 (29.5) 
 
21 (28.0) 31 (31.10 29 (33.7) 15 (31.3) 0.650 
Occasionally 128 (39.4) 28 (37.3) 46 (44.7) 35 (40.7) 19 (39.6)  
Weekly 88 (27.1) 26 (34.7) 26 (25.2) 22 (25.6) 14 (29.2)  
Current medication, n (%)       
Aspirin 107 (33.2) 20 (26.7) 34 (31.8) 36 (38.7) 17 (36.2) 0.392 
Lipid lowering 270 (83.1) 61 (81.3) 88 (82.2) 78 (83.9) 43 (86.0) 0.641 
Anti-hypertensive 245 (75.4) 53 (70.7) 82 (76.6) 71 (76.3) 39 (78.0) 0.748 
Thyroid medication 29 (9.0) 6 (8.0) 6 (5.6) 12 (12.9) 5 (10.4) 0.327 
Anti-obesity 4 (1.2) 0 2 (1.8) 0 2 (4.1) 0.127 
Steroids  30 (9.3) 5 (6.7) 8 (7.5) 12 (12.9) 5 (10.4) 0.467 
Previous severe hypoglycaemia, n (%)       
never  200 (61.5) 60 (80.0) 63 (58.9) 42 (45.2) 35 (70.0) 0.001 
Previous non-severe hypoglycaemia, n 
 
      
never  123 (37.8) 40 (53.3) 37 (34.6) 16 (17.2) 30 (60.0) <0.001 
Hypo awareness score (1-7)**;  
                                      mean (±SD) 
3.15 (2.16) 4.43 (2.22) 3.00 (2.05) 2.57 (1.04) 3.25 (2.27) <0.001 
median (IQR)  2.5 [1-5] 5 [3-7] 2 [1-5] 2 [1-4] 2.5 [1-5] <0.001 
^ĐŽƌĞш ? 77 (40.5) 24 (64.9) 26 (40.6) 18 (26.1) 9 (45.0) 0.002 
Score < 4 113 (59.5) 13 (35.1) 38 (59.4) 51 (73.9) 11 (55.0)  
 
Data given as mean (±SD) for continuous outcomes, unless otherwise stated, and n (%) for categorical. 
* P-values are estimated using chi-square for categorical variables and one-way anova or Kruskal Wallis for continuous 
variables.  
+\SRDZDUHQHVVVFRUHDOZD\VDZDUHWRQHYHUDZDUHDVFRUHRILPSOLHVLPSDLUHGDZDUHQHVV  
BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high density 
lipoprotein; LDL, low density lipoprotein; 
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Table 2: Experience of hypoglycaemia HSLVRGHVSURSRUWLRQKDYLQJHSLVRGH 
 
Category and how identified 
 
All (n=274) 
n (% ; 95% CI) 
Metformin (n=64) 
n (% ; 95% CI) 
Sulfonylurea (n=91) 
n (% ; 95% CI) 
p-value Insulin (n=78) 
n (% ; 95% CI) 
p-value Incretin-based 
(n=41) 
n (% ; 95% CI) 
p-value 
         
Any hypoglycaemia episode 107 (39.2; 33.4 to 
45.0) 
12 (18.8; 10.9 to 30.3)   47 (51.6; 41.4 to 61.8) <0.001 44 (56.4; 45.2 to 67.0) <0.001 4 (9.8; 3.6 to 23.6) 0.211 
          
Symptomatic hypoglycaemia - all 87 (31.8; 26.5 to 37.5) 12 (18.8; 10.9 to 30.3) 34 (37.4; 28.0 to 47.8) 0.013 37 (47.4; 36.5 to 58.6) <0.001 4 (9.8; 3.6 to 23.6) 0.211 
         
Symptomatic  
- ůŽŽĚŐůƵĐŽƐĞш ? ? ?ƚŽч ? ? ?ŵŵŽů ?> 
63 (23.0; 18.4 to 28.4) 5 (7.8; 3.3 to 17.6)  25 (27.5; 19.2 to 37.6) 0.002 29 (37.2; 27.1 to 48.5) <0.001 4 (9.8; 3.6 to 23.6) 0.729 
         
Symptomatic  
 - Blood glucose < 3.0 mmol/L 
26 (9.5; 6.5 to 13.6)  0 6 (6.6; 3.0 to 14.0) 0.036 19 (24.4; 16.0 to 35.2)  <0.001 1 (2.4; 0.3 to 15.9) 0.209 
         
Non-severe 
- No assistance required 
98 (35.8; 30.3 to 41.7) 
 
11 (17.2; 9.7 to 28.6) 44 (48.4; 38.2 to 58.6) <0.001 40 (51.3; 40.2 to 62.2) <0.001 3 (7.3; 2.3 to 20.7) 0.147 
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Severe  
 - Assistance required 
18 (6.6; 4.2 to 10.2) 3 (4.7;1.5 to 13.7) 4  (4.4; 1.6 to 11.2) 0.931 9 (11.5; 6.1 to 20.8) 0.144 2 (4.9; 1.2 to 17.9) 0.964 
         
Nocturnal hypoglycaemia - all 57 (20.8; 16.4 to 26.1)  5 (7.8; 3.3 to 17.7) 18 (19.8; 12.8 to 29.3) 0.039 32 (41.0; 30.6 to 52.3)  <0.001 2 (4.9; 1.2 to 17.9) 0.556 
p-value, metformin is the reference group 
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Table 3: Incidence of hypoglycaemia (per person-year by treatment group) 
 
 
All Metformin Sulfonylurea   Insulin   Incretin-based 
 
 
 IR 
(95% CI) 
IR  
(95% CI) 
IR  
(95% CI) 
IRR  
(95% CI) 
p-
value 
IR  
(95% CI) 
IRR  
(95% CI) 
p-
value 
IR  
(95% CI) 
IRR  
(95% CI) 
p-
value 
            
Any hypoglycaemia 
episode 
2.26 
(1.92 to 2.65) 
0.76 
(0.49 to 1.18) 
2.34 
(1.77 to 3.10) 
3.09 
(1.83 to 5.21) 
<0.001 
4.39 
(3.33 to 5.78) 
5.79 
(3.44 to 9.74) 
<0.001 
0.56 
(0.31 to 1.01) 
0.74 
(0.36 to 1.55) 
0.427 
            
Symptomatic 
hypoglycaemia - all 
1.79 
(1.51 to 2.11) 
0.76 
(0.49 to 1.18) 
1.91 
(1.43 to 2.54) 
2.52 
(1.48 to 4.26) 
0.001 
3.10 
(2.35 to 4.09) 
4.09 
(2.43 to 6.89) 
<0.001 
0.48 
(0.26 to 0.89) 
0.64 
(0.30 to 1.36) 
0.245 
            
Symptomatic 
- ůŽŽĚŐůƵĐŽƐĞш ? ? ?
ƚŽч ? ? ?mmol/L 
 
0.92 
(0.76 to 1.12) 
 
0.18 
(0.09 to 0.38) 
 
1.14 
(0.83 to 1.58) 
 
6.29 
(2.79 to 14.16) 
 
<0.001 
 
1.67 
(1.22 to 2.28) 
 
9.16 
(4.08 to 20.5) 
 
<0.001 
 
0.14 
(0.05 to 0.40) 
 
0.79 
(0.22 to 2.81) 
 
0.711 
            
Symptomatic - Blood 
glucose < 3.0 mmol/L 
0.35 
(0.26 to 0.46) 
- 
0.12 
(0.06 to 0.26) 
-  
1.03 
(0.72 to 1.47) 
-  
0.04 
(0.00 to 0.26) 
-  
            
Non-severe 
- No assistance 
1.93 
(1.63 to 2.27) 
0.64 
(0.41 to 1.02) 
1.94 
(1.46 to 2.59) 
3.02 
(1.76 to 5.18) 
<0.001 
3.84 
(2.90 to 5.09) 
5.96 
(3.48 to 10.2) 
<0.001 
0.49 
(0.26 to 0.90) 
0.75 
(0.35 to 1.63) 
0.470 
            
Severe 
- Assistance required 
0.15 
(0.11 to 0.23) 
0.07 
(0.02 to 0.23) 
0.09 
(0.04 to 0.22) 
1.33 
(0.32 to 5.59) 
0.692 
0.32 
(0.19 to 0.53) 
4.55 
(1.28 to 16.2) 
0.019 
0.07 
(0.02 to 0.30) 
1.01 
(0.16 to 6.36) 
0.991 
            
Nocturnal 
hypoglycaemia - all 
0.59 
(0.47 to 0.74) 
0.18 
(0.09 to 0.39) 
0.49 
(0.32 to 0.75) 
2.67 
(1.13 to 6.28) 
0.025 
1.37 
(0.97 to 1.95) 
7.48 
(3.29 to 17.0) 
<0.001 
0.07 
(0.02 to 0.29) 
0.38 
(0.08 to 1.89) 
0.238 
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IR, Incidence Rate 
IRR, Incidence Rate Ratio (metformin as a reference group) 
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